Markets closed

Johnson & Johnson

JNJ · NYSE

Symbol: JNJ
Type: Stock
Sector: Health Care
Industry: Pharmaceutical Preparations
Exchange: NYSE

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sectors global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://www.jnjmedtech.com/en-US/. Follow us at @JNJMedTech on LinkedIn. ACUVUE is a Johnson & Johnson company.

Key Issues

Bullish view

J&J’s valuation may look more attractive when STELARA is not treated as the sole determinant of future performance, because the company has other medicines and a broad MedTech portfolio.

Bearish view

STELARA remains important enough that any erosion in its contribution could weigh on earnings and make the stock appear expensive unless replacement products scale successfully.

Analyst Consensus

See all

Buy

22 analysts

$266

Current

—

Low

$282

Average

—

High

Average target implies +5.89% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Analyst Consensus

Buy

22 analysts

$266

Current

—

Low

$282

Average

—

High

Average target implies +5.89% versus the current price.

Analyst Ratings Synthesis

The supplied consensus is Buy across 22 analysts, with a mean price target of $282. The evidence provides neither a low nor a high target, so it does not establish where targets cluster or how wide the target spread is. No named analyst or firm is identified as the most or least bullish. No rating or target revisions are explicitly reported during the week, preventing a supported conclusion about revision direction. The substantive disagreement visible in the supplied research concerns whether STELARA-related exposure makes J&J expensive, whether a potential orthopedics divestiture would unlock value or weaken diversification, and whether pipeline progress can offset clinical setbacks. Those debates explain the uncertainty around valuation but are not tied to individual analyst targets.